摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Povafonidine | 177843-85-5

中文名称
——
中文别名
——
英文名称
Povafonidine
英文别名
N-(4,5-dihydro-1H-imidazol-2-yl)-4-methyl-1H-benzimidazol-5-amine
Povafonidine化学式
CAS
177843-85-5
化学式
C11H13N5
mdl
——
分子量
215.25
InChiKey
KPMVPPWUQFJHCX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    65.1
  • 氢给体数:
    3
  • 氢受体数:
    2

文献信息

  • [EN] 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY<br/>[FR] 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE, DERIVES ET PROCEDES DE PREPARATION ET D'UTILISATION DE CES DERNIERS EN TANT QU'AGONISTES DU RECEPTEUR ALPHA-ADRENERGIQUE AYANT UNE MEILLEURE STABILITE METABOLIQUE
    申请人:PROCTER & GAMBLE
    公开号:WO1999026942A1
    公开(公告)日:1999-06-03
    The present invention is directed to compounds having a structure according formula (I), wherein: (a) R1 is alkyl; (b) R2 is selected from the group consisting of: hydrogen, alkyl, methoxy, cyano, and halo; (c) R3 is selected from the group consisting of: hydrogen, methyl, hydroxy, cyano and halo; (d) R4 is selected from the group consisting of: hydrogen, methyl, ethyl and isopropyl; (e) R5 is selected from the group consisting of: hydrogen, methyl, amino, methoxy, hydroxy, cyano and halo; (f) provided that at least one of R2, R3, R4 or R5 is other than hydrogen or fluorine; (g) provided that when R1 is methyl and both R2 and R5 are hydrogen, R3 is other than methyl or halo; (h) provided that when R3 is cyano, R1 is methyl; and any tautomer of the structure or a pharmaceutically acceptable salt, or biohydrolyzable ester, amide, or imide thereof. The compounds of the present invention are peripherally acting selective alpha-2 adrenergic compounds that lower CNS activity and that resist metabolic transformation into undesirable compounds.
    本发明涉及具有以下式(I)的结构的化合物,其中:(a)R1是烷基;(b)R2选自以下组:氢,烷基,甲氧基,基和卤素;(c)R3选自以下组:氢,甲基,羟基,基和卤素;(d)R4选自以下组:氢,甲基,乙基和异丙基;(e)R5选自以下组:氢,甲基,基,甲氧基,羟基,基和卤素;(f)至少有一个R2,R3,R4或R5不是氢或;(g)当R1是甲基且R2和R5均为氢时,R3不是甲基或卤素;(h)当R3是基时,R1是甲基;以及该结构的任何互变异构体或药学上可接受的盐,或可生物解的酯,酰胺或亚胺。本发明的化合物是周围作用的选择性α-2肾上腺素化合物,可以降低中枢神经系统的活性,并抵抗代谢转化为不良化合物。
  • Novel benzimidazole derivatives
    申请人:Synaptic Pharmaceutical Corporation
    公开号:US20030181730A1
    公开(公告)日:2003-09-25
    This invention provides compounds having the structure: 1 wherein each of R 1 , R 2 , R 3 and R 9 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R 1 is present, R 3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R 3 is present, R 1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R 4 , R 5 and R 6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR 7 , —CN, —COR 7 , —CO 2 R 7 , —CON(R 7 ) 2 , —OCOR 7 , —SR 7 , —N(R 7 ) 2 , —NR 7 COR 7 , —(CH 2 ) n OR 7 , —(CH 2 ) n N(R 7 ) 2 , —(CH 2 ) n NR 7 COR 7 , wherein n is an integer from 1 to 4; and wherein each of R 7 and R 8 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.
    本发明提供具有结构的化合物:1其中R1,R2,R3和R9中的每一个都是独立的H; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; C3-C7环烷基或环烯基; 酰基,苯基,取代苯基或杂环基; 其中每个虚线代表单键或双键,前提是如果R1存在,则R3不存在,并且在位置3处的N和位置2处的C之间有双键,在位置2处的C和位置1处的N之间有单键,如果R3存在,则R1不存在,并且在位置1处的N和位置2处的C之间有双键,在位置2处的C和位置3处的N之间有单键; 其中R4,R5和R6中的每一个都是独立的H,F,Cl,Br,I; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; C3-C7环烷基或环烯基; 苯基,取代苯基,杂环基,—OH,—OR7,—CN,—COR7,—CO2R7,—CON(R7)2,—OCOR7,—SR7,—N(R7)2,—NR7COR7,—(CH2)nOR7,—( )nN(R7)2,—( )nNR7COR7,其中n是1到4的整数; 其中R7和R8中的每一个都是独立的H; 直链或支链,取代或未取代的C1-C7烷基,C2-C7烯基或炔基; 苯基或取代苯基。 这些化合物对克隆的人类α2受体具有选择性,并可用作镇痛,镇静或麻醉剂
  • Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
    申请人:Allergan, Inc.
    公开号:US11077053B2
    公开(公告)日:2021-08-03
    Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.
    使用式 I 的α-2-肾上腺素能受体激动剂的方法: 描述了用于改善视力的方法,例如用于治疗老花眼、夜视力差、眩光、视星光、视晕和某些形式的近视(如夜近视)等眼部疾病。
  • PROCESS FOR MAKING 2-AMINO-2-IMIDAZOLINE, GUANIDINE, AND 2-AMINO-3,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES
    申请人:THE PROCTER & GAMBLE COMPANY
    公开号:EP0944603B1
    公开(公告)日:2003-02-19
  • 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS
    申请人:THE PROCTER & GAMBLE COMPANY
    公开号:EP0736022A1
    公开(公告)日:1996-10-09
查看更多